Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells

被引:33
|
作者
Fu, Hai-Ying [1 ]
Shen, Jian-Zhen [1 ]
Wu, Yong [1 ]
Shen, Song-Fei [1 ]
Zhou, Hua-Rong [1 ]
Fan, Li-Ping [1 ]
机构
[1] Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Fuzhou 350001, Fujian, Peoples R China
关键词
methylation; arsenic trioxide; hematologic malignancies; gene reactivation; CDKN2B and CDKN2A genes; LEUKEMIA-CELLS; HUMAN CANCERS; CPG ISLANDS; HYPERMETHYLATION; HYPOMETHYLATION; ASSOCIATION; MECHANISMS; APOPTOSIS; PROTEIN;
D O I
10.3892/or_00000864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclin-dependent kinase inhibitors CDKN2B and CDKN2A are tumor suppressor genes that are frequently dysregulated in a variety of cancers. Aberrant regulation via DNA hypermethylation causes gene silencing. Arsenic trioxide has been successfully used to treat malignant, hematopoietic diseases and is known to act by induction of apoptosis and inhibition of cellular proliferation. However, arsenic trioxide has been recently reported to act via inhibition of DNA hypermethylation in some solid tumors. The goal of this study was to explore the mechanism of arsenic trioxide induced demethylation of the CDKN2B and CDKN2A promoters in the hematologic malignant cell lines Molt4, MUTZ-1, U937, U266 and CA46. We used bisulphate modification and nested-methylation specific PCR to determine the levels of methylated and unmethylated promoter sequences in untreated and As2O3-treated cells. We used semi-quantitative RT-PCR and immunoblotting to quantify CDKN2B and CDKN2A mRNA and protein levels, respectively. We measured DNMT activity in nuclear extracts of untreated and treated cells using radiolabeled SAM as a methyl donor. The CDKN2B promoter was hypermethylated in Molt4 and MUTZ-1 cells, while the CDKN2A promoter was hypermethylated in U937, U266 and CA46 cells. As2O3 treatment caused demethylation associated with an increase in mRNA levels of the CDKN2B and CDKN2A genes. We also demonstrated a concomitant inhibition in DNMT activity and DNMT mRNA levels in As2O3-treated cells. In summary, As2O3 restored expression levels of tumor suppressor genes in hematologic malignant cells by causing promoter demethylation along with an inhibition of DNMTs 1, 3a and 3b.
引用
收藏
页码:335 / 343
页数:9
相关论文
共 50 条
  • [1] Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells
    Cui, X
    Wakai, T
    Shirai, Y
    Yokoyama, N
    Hatakeyama, K
    Hirano, S
    HUMAN PATHOLOGY, 2006, 37 (03) : 298 - 311
  • [2] Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide
    Au, WY
    Fung, AT
    Ma, ES
    Chan, CH
    Wong, KF
    Chim, CS
    Liang, RH
    Kwong, YL
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (05) : 632 - 635
  • [3] Methylation patterns of the CDKN2B and CDKN2A genes in an indigenous population exposed to pesticides
    Paredes-Cespedes, Diana M.
    Bernal-Hernandez, Yael Yvette
    Herrera-Moreno, Jose Francisco
    Rojas-Garcia, Aurora Elizabeth
    Medina-Diaz, Irma Martha
    Gonzalez-Arias, Cyndia A.
    Barron-Vivanco, Briscia Socorro
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [4] Methylation patterns of the CDKN2B and CDKN2A genes in an indigenous population exposed to pesticides
    Paredes-Cespedes, Diana M.
    Bernal-Hernandez, Yael Yvette
    Herrera-Moreno, Jose Francisco
    Rojas-Garcia, Aurora Elizabeth
    Medina-Diaz, Irma Martha
    Gonzalez-Arias, Cyndia A.
    Barron-Vivanco, Briscia Socorro
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [5] Trichosanthin inhibits DNA methyltransferase and restores methylation-silenced gene expression in human cervical cancer cells
    Huang, Yiling
    Song, Huamei
    Hu, Huojun
    Cui, Lei
    You, Chengcheng
    Huang, Liming
    MOLECULAR MEDICINE REPORTS, 2012, 6 (04) : 872 - 878
  • [6] METHYLATION CHANGES IN CDKN2B AND CDKN2A GENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Cechova, H.
    Pegova, K.
    Zizkova, R.
    Jencik, J.
    Stankova, M.
    Hrabakova, P.
    Cermak, J.
    HAEMATOLOGICA, 2012, 97 : 576 - 576
  • [7] CDKN2A and CDKN2B methylation in coronary heart disease cases and controls
    Zhong, Jinyan
    Chen, Xiaoying
    Ye, Huadan
    Wu, Nan
    Chen, Xiaomin
    Duan, Shiwei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (06) : 6093 - 6098
  • [8] INTRAGENIC MUTATIONS OF CDKN2B AND CDKN2A IN PRIMARY HUMAN ESOPHAGEAL CANCERS
    SUZUKI, H
    ZHOU, XL
    YIN, J
    LEI, JY
    JIANG, HY
    SUZUKI, Y
    CHAN, T
    HANNON, GJ
    MERGNER, WJ
    ABRAHAM, JM
    MELTZER, SJ
    HUMAN MOLECULAR GENETICS, 1995, 4 (10) : 1883 - 1887
  • [9] Genetic study of the CDKN2A and CDKN2B genes in renal cell carcinoma patients
    Kiatprungvech, Nattaradee
    Sangkum, Premsant
    Malinee, Rozita
    Sommaluan, Suchada
    Korkiatsakul, Veerawat
    Worawichawong, Suchin
    Rerkamnuaychoke, Budsaba
    Kongruang, Adcharee
    Aeesoa, Suraida
    Lertsithichai, Panuwat
    Kijvikai, Kittinut
    Kongchareonsombat, Wisoot
    Siriboonpiputtana, Teerapong
    PRACTICAL LABORATORY MEDICINE, 2024, 40
  • [10] DNA METHYLATION OF CDKN2B/CDKN2B-AS1 LOCUS ENHANCER IN ATHEROSCLEROSIS
    Goncharova, I. A.
    Markov, A. V.
    Koroleva, U. A.
    Babushkina, N. P.
    Salakhov, R. R.
    Sharysh, D. V.
    Sleptcov, A. A.
    Valiahmetov, N. R.
    Nazarenko, M. S.
    Puzyrev, V. P.
    ATHEROSCLEROSIS, 2020, 315 : E54 - E55